Serial No.: 10/535,002 -3-

We claim:

(currently amended) A compound of Formula I:

where:

Ar is OF a heterocycle selected from the group consisting of 2,3

dihydrobenzo[1,4]dioxin 6 yl, 2,3 dihydrobenzofur 5 yl, benzo[1,3]dioxol 5 yl, 1- $(C_4 \cdot C_6 \cdot alkyt)$ indolin 6 yl, benzothien-2-yl, benzothien-5-yl, and benzothien-6-yl, 6 $(C_4 \cdot C_6 \cdot alkyt)$ benzothien 2 yl, 6 $(C_4 \cdot C_6 \cdot alkyt)$ benzothien 2 yl, benzofur 6 yl, thieno[3,2 b]pyridin 2 yl, and 1 $(C_4 \cdot C_6 \cdot alkyt)$ indol 2 ył;

A is phenyl, benzofuryl, eyelopentadienyl, eyelobutyl, or a cyclopentyl that is optionallysubstituted at one of the two carbons adjacent to the ring fusion of the cyclopentylwith an oxo moiety;

 R^1 and R^2 are either both halo, both trifluoromethyl, or one is halo and the other is C_1 - C_6 alkyl; or

a pharmaceutically acceptable base addition salt thereof.

- (original) The compound of claim 1, wherein the compound is a pharmaceutically acceptable base addition salt.
- 3. (original) The compound of claim 2, wherein the pharmaceutically acceptable base addition salt is a sodium salt.
- (currently amended) A method of treating susceptible neoplasms in a mammal comprising administering to a mammal in need of such treatment an oncolytically effective amount of a compound of Formula I:

where:

Ar is

•F a heterocycle selected from the group consisting of 2,3dihydrobenzo[1,4]dioxin 6-yl, 2,3-dihydrobenzofur 5-yl, benzo[1,3]dioxol 5-yl, 1(C4-C6-alkyl)indolin 6-yl, benzothien-2-yl, benzothien-5-yl, and benzothien-6-yl,5(C4-C6-alkyl)benzothien 2-yl, 6-(C4-C6-alkyl)benzothien 2-yl, benzothiazol 6-yl,

benzofur 2 yl, benzofur 6 yl, thieno[3,2-b]pyridin 2 yl, and 1 (C4-C6 alkyl)indol-2 yl

A is phenyl, benzofuryl, cyclopentadienyl, cyclobutyl, or a cyclopentyl that is optionally substituted at one of the two carbons adjacent to the ring fusion of the cyclopentyl with an exe moiety:

 R^1 and R^2 are either both halo, both trifluoromethyl, or one is halo and the other is C_1 - C_6 alkyl; or

a pharmaceutically acceptable base addition salt thereof.

 (currently amended) A pharmaceutical formulation comprising a compound of Formula I:

where:

Serial No.: 10/535,002 -5-



Ar is or a heterocycle selected from the group consisting of 2,3

$$\begin{split} & \text{dihydrobenzo}[1,4] \\ & \text{dioxin 6 yl, 2,3 dihydrobenzofur 5 yl, benzo}[1,3] \\ & \text{dioxol 5 yl, benzoftien-2 yl, benzothien-5 yl, and benzothien-6 yl, 5-} \\ & \text{(C_k-C_k-alky1)} \\ & \text{benzothien-2 yl, 6-(C_k-C_k-alky1)} \\ & \text{benzofur 6 yl, thiene}[3,2-b] \\ & \text{pyridin 2 yl, benzofur 6 yl, thiene}[3,2-b] \\ & \text{yridin 2 yl, and 1 (C_k-C_k-alky1)} \\ & \text{diny}[3,2-b] \\ & \text{d$$

A is phenyl, benzofuryl, cyclopentadienyl, cyclobutyl, or a cyclopentyl that is optionallysubstituted at one of the two earbons adjacent to the ring fusion of the cyclopentylwith an oxo moiety;

 R^1 and R^2 are either both halo, both trifluoromethyl, or one is halo and the other is C_1 - C_6 alkyl; or

a pharmaceutically acceptable base addition salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.